EirGenix
Delivering Experience-Packed Contract Manufacturing Services

Any piece of writing in 2020 beginning with the COVID-19 pandemic as its subject has become commonplace and understandably so. And when addressing the business operations of pharmaceutical and life science outsourcing companies, the conversation is unavoidable. For an industry that constantly faces changes in its market demands regardless of a global health crisis, the fact that organisations require the most meticulous CDMO services today is increasingly conspicuous. Dr. Lee-Cheng Liu, Ph.D. in Chemical Engineering and Applied Chemistry, further supports this idea by stating that the changing market conditions will require contract development and manufacturing organisations (CDMO) to adapt to current regulations and demands quickly, allowing them to stay both relevant and fully functional. Without proper research and planning for the business’ future, a CDMO can easily lose its competitiveness in the market and fail to meet the bottom line. “The pandemic has been a clear example of the need for industry players to be adaptive to change, and the massive shift towards prioritising COVID-19-related projects has postponed the completion of projects in many companies,” adds Dr. Liu. In order to help companies circumvent such challenges, EirGenix, an internationally acclaimed CDMO, offers a slew of effective biologics CDMO services at affordable prices, all the while strengthening their compliance and ability to perform in the market.

The company was founded on the grounds of leveraging a dual business model that follows the principles of internal product development of biologics/biosimilar and a biologics-based CDMO. “EirGenix excels in developing monoclonal antibodies (mAb), bispecific mAbs, fusion proteins, recombinant proteins, protein vaccines, and plasmid DNAs,” expresses Dr. Liu, who currently drives innovation within the company as its President and CEO.

Since its inception in 2012, EirGenix has observed exponential growth till date and has constructed its very own commercial manufacturing facility in Zhubei, Taiwan, which stands to be the largest biopharmaceutical manufacturing establishment in the country.

EirGenix provides full-scope services from cell line development and process optimisation to small-scale and commercial good manufacturing practices (GMP) certified services for both mammalian and microbial cell-based biologics. Depending on a client’s needs, the company adopts an elaborate approach to product development by leveraging its staff ’s vast experiences and additionally offers a proprietary CHO-K1 cell line with exceptional titer performance. “Our facilities are PIC/S GMP-compliant and operate with the highest level of efficiency, ensuring that we deliver both high-quality and cost-effective products,” says Dr. Liu. Moreover, with the belief that access to healthcare is a basic human right, EirGenix’s staff understands that they have a social responsibility to uphold and strive to provide affordable, biologic medicines for everyone.

To further elucidate his company’s competencies, Dr. Liu shares the case study of an American client that reached out to EirGenix to handle two important projects that were originally meant for a CDMO in China. According to the client, although the previous CDMO claimed that they had solid experience, it was not properly passed on to their junior staff due to a high employee turnover rate, therefore their project encountered significant obstacles and difficulties. Conversely, every individual on EirGenix’s shopfloor is well-trained and maintains the necessary experience to satisfy the client’s demands. From process development till GMP manufacturing, Dr. Liu’s team excelled in delivering on the client’s expectations and continued to subscribe to EirGenix’s services for four additional CDMO projects.

With such comprehensive subject matter expertise and over 60 successful project completions, the company is empowering organisations all over the world. EirGenix, in collaboration with two Taiwanese biotechnology companies, has developed a COVID-19 antigen rapid-test, which is now the first Taiwanese FDA approved antigen test for emergency purposes. Dr. Liu and his company are currently leading the charge in addressing biopharmaceutical companies’ manufacturing needs and intend to continue driving change for the development of more affordable, high-quality medicine across the globe.